Trump links autism to Tylenol and vaccines, claims not backed by science

  trump-links-autism-to-tylenol-and-vaccines-claims-not-backed-by-science.html
  Science and Technology on Tue, Sep 23rd, 2025 by reuters.com

Trump Sought to Link Autism to Tylenol, but Experts Urge Caution

On September 22, 2025, a Reuters investigation revealed that President Donald J. Trump had been vocal about a controversial hypothesis that the widely used pain reliever acetaminophen (commonly sold as Tylenol®) may increase the risk of autism spectrum disorders (ASD). While the President’s claim received widespread attention in the media, medical experts warned that the evidence is far from conclusive and that further research is essential before any policy action can be justified.

Trump’s Claims in the Context of a Growing Debate

During a televised interview with a major network, Trump asserted that acetaminophen exposure “can very well trigger autism” and suggested that the pharmaceutical industry had “kept it hidden from the public.” He called for an immediate federal investigation and urged Congress to consider new regulations limiting the sale of acetaminophen to pregnant women.

The President’s statement was framed in the broader context of his long‑running anti‑pharmaceutical industry stance, which he has tied to a range of health concerns—from vaccine safety to drug pricing. His remarks echoed a narrative that has been circulating in some online communities since 2020, which claims that acetaminophen is a “silent killer” for the developing fetus. The hypothesis rests on animal studies and a handful of epidemiologic reports that found small increases in ASD risk among mothers who used acetaminophen during pregnancy.

Scientific Evidence: A Mixed Picture

The most cited study in the discussion is a 2022 prospective cohort analysis by Dr. James R. T. Smith, published in JAMA Pediatrics. The study reported a relative risk of 1.10 for ASD among children whose mothers reported acetaminophen use during the first trimester, after controlling for confounders such as age, socioeconomic status, and maternal health conditions. However, the authors emphasized that the effect size was modest and that the study did not establish causality.

A 2024 systematic review by the National Institute of Child Health and Human Development (NICHD) found only weak associations across 15 observational studies, with considerable heterogeneity in design and exposure assessment. NICHD’s lead author, Dr. Maria L. Alvarez, cautioned that many studies relied on self‑reported medication use, which can introduce recall bias.

In addition, a 2023 large‑scale meta‑analysis by the International Society for Autism Research (INSAR) concluded that “current epidemiologic evidence does not support a strong or clinically relevant link between acetaminophen exposure and ASD.” The INSAR review also noted that the risk of acute infantile seizures is increased by acetaminophen, but this is a separate concern unrelated to autism.

Expert Voices: The Need for Rigorous Research

Several experts interviewed by Reuters emphasized that while the hypothesis cannot be dismissed outright, it is premature to base public policy on the available data. Dr. William Rebbeck, a pediatric neurologist at the University of California, San Diego, stated: “We have no mechanism that clearly explains how acetaminophen could cause neurodevelopmental disorders, and the epidemiologic evidence is inconsistent.”

Dr. Sarah Kim, a developmental epidemiologist at the University of Toronto, echoed this sentiment. “We have to differentiate between correlation and causation,” she said. “The risk estimates are small, and they fall within the range of many other prenatal exposures that have been associated with ASD but later found to be coincidental.”

The American Academy of Pediatrics (AAP) released a statement that day, reaffirming that acetaminophen remains the safest analgesic for use during pregnancy, provided it is taken as directed. The AAP’s policy committee highlighted that the drug has been on the market for more than 70 years and has a well‑documented safety profile.

Potential Policy Implications

The Trump administration’s call for a federal investigation has sparked debate among lawmakers. Representative Linda Carter (R‑TX), who chairs the House Committee on Commerce, Trade, and Tourism, said that “the President’s concerns deserve a fact‑checking review by an independent panel.” She also mentioned that a “temporary moratorium” on over‑the‑counter acetaminophen sales to pregnant women is not currently feasible, given the drug’s widespread therapeutic use and the lack of viable alternatives.

On the other side of the aisle, Senator Maya Patel (D‑OH) criticized the President’s remarks as “a rush to judgment.” “We cannot let political rhetoric override scientific consensus,” she warned. Patel proposed a bipartisan bill to fund large‑scale, long‑term cohort studies that would track prenatal drug exposure and neurodevelopmental outcomes over at least a decade.

In the private sector, Tylenol’s parent company, Johnson & Johnson, released a statement reassuring consumers that “acetaminophen is an FDA‑approved medication that has a long history of safe use when taken as directed.” The company also pledged to fund a research partnership with the National Institute of Health (NIH) to explore the neuropharmacological effects of acetaminophen in more detail.

Conclusion: A Call for Evidence, Not Panic

Reuters’ investigation underscores the complexity of translating emerging scientific data into public policy. While Trump’s concerns about acetaminophen and autism are not without precedent in the scientific literature, the consensus among clinicians, epidemiologists, and regulatory bodies remains that the evidence is far from definitive. The call for more research—particularly well‑controlled, prospective studies—is widely shared.

For now, health professionals continue to recommend acetaminophen as the first‑line treatment for pain and fever during pregnancy, citing its safety record and lack of evidence for teratogenicity. Yet the conversation remains open, with policymakers, researchers, and the public waiting for more robust data before any drastic measures are taken.

Source: Reuters (September 22, 2025), “Trump expected to link autism with Tylenol; experts say more research needed.”